98 related articles for article (PubMed ID: 28678239)
1. Quantitative and correlative biodistribution analysis of
Kramer L; Winter G; Baur B; Kuntz AJ; Kull T; Solbach C; Beer AJ; Lindén M
Nanoscale; 2017 Jul; 9(27):9743-9753. PubMed ID: 28678239
[TBL] [Abstract][Full Text] [Related]
2. In Vivo Integrity and Biological Fate of Chelator-Free Zirconium-89-Labeled Mesoporous Silica Nanoparticles.
Chen F; Goel S; Valdovinos HF; Luo H; Hernandez R; Barnhart TE; Cai W
ACS Nano; 2015 Aug; 9(8):7950-9. PubMed ID: 26213260
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, characterization, and biodistribution of multiple 89Zr-labeled pore-expanded mesoporous silica nanoparticles for PET.
Miller L; Winter G; Baur B; Witulla B; Solbach C; Reske S; Lindén M
Nanoscale; 2014 May; 6(9):4928-35. PubMed ID: 24675844
[TBL] [Abstract][Full Text] [Related]
4. Etoposide encased folic acid adorned mesoporous silica nanoparticles as potent nanovehicles for enhanced prostate cancer therapy: synthesis, characterization, cellular uptake and biodistribution.
Saroj S; Rajput SJ
Artif Cells Nanomed Biotechnol; 2018; 46(sup3):S1115-S1130. PubMed ID: 30669865
[TBL] [Abstract][Full Text] [Related]
5. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.
Verel I; Visser GW; Boellaard R; Boerman OC; van Eerd J; Snow GB; Lammertsma AA; van Dongen GA
J Nucl Med; 2003 Oct; 44(10):1663-70. PubMed ID: 14530484
[TBL] [Abstract][Full Text] [Related]
6. Impact of surface grafting density of PEG macromolecules on dually fluorescent silica nanoparticles used for the in vivo imaging of subcutaneous tumors.
Adumeau L; Genevois C; Roudier L; Schatz C; Couillaud F; Mornet S
Biochim Biophys Acta Gen Subj; 2017 Jun; 1861(6):1587-1596. PubMed ID: 28179102
[TBL] [Abstract][Full Text] [Related]
7. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor.
Smith-Jones PM; Vallabhajosula S; Navarro V; Bastidas D; Goldsmith SJ; Bander NH
J Nucl Med; 2003 Apr; 44(4):610-7. PubMed ID: 12679407
[TBL] [Abstract][Full Text] [Related]
8. In Vivo Tracking of the Degradation of Mesoporous Silica through
Bindini E; Ramirez MLA; Rios X; Cossío U; Simó C; Gomez-Vallejo V; Soler-Illia G; Llop J; Moya SE
Small; 2021 Jul; 17(30):e2101519. PubMed ID: 34145769
[TBL] [Abstract][Full Text] [Related]
9. Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with ⁸⁹Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts.
ter Weele EJ; Terwisscha van Scheltinga AG; Kosterink JG; Pot L; Vedelaar SR; Lamberts LE; Williams SP; Lub-de Hooge MN; de Vries EG
Oncotarget; 2015 Dec; 6(39):42081-90. PubMed ID: 26536664
[TBL] [Abstract][Full Text] [Related]
10. In vivo biodistribution and urinary excretion of mesoporous silica nanoparticles: effects of particle size and PEGylation.
He Q; Zhang Z; Gao F; Li Y; Shi J
Small; 2011 Jan; 7(2):271-80. PubMed ID: 21213393
[TBL] [Abstract][Full Text] [Related]
11. Biodistribution and Excretion of Intravenously Injected Mesoporous Silica Nanoparticles: Implications for Drug Delivery Efficiency and Safety.
Lindén M
Enzymes; 2018; 43():155-180. PubMed ID: 30244806
[TBL] [Abstract][Full Text] [Related]
12. The fate of MAb-targeted Cd(125m)Te/ZnS nanoparticles in vivo.
Kennel SJ; Woodward JD; Rondinone AJ; Wall J; Huang Y; Mirzadeh S
Nucl Med Biol; 2008 May; 35(4):501-14. PubMed ID: 18482688
[TBL] [Abstract][Full Text] [Related]
13. Antibody-functionalized nanoparticles for imaging cancer: influence of conjugation to gold nanoparticles on the biodistribution of 89Zr-labeled cetuximab in mice.
Karmani L; Labar D; Valembois V; Bouchat V; Nagaswaran PG; Bol A; Gillart J; Levêque P; Bouzin C; Bonifazi D; Michiels C; Feron O; Grégoire V; Lucas S; Vander Borght T; Gallez B
Contrast Media Mol Imaging; 2013; 8(5):402-8. PubMed ID: 23740810
[TBL] [Abstract][Full Text] [Related]
14. Intracellular cleavable poly(2-dimethylaminoethyl methacrylate) functionalized mesoporous silica nanoparticles for efficient siRNA delivery in vitro and in vivo.
Lin D; Cheng Q; Jiang Q; Huang Y; Yang Z; Han S; Zhao Y; Guo S; Liang Z; Dong A
Nanoscale; 2013 May; 5(10):4291-301. PubMed ID: 23552843
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, characterization, and biodistribution studies of (99m)Tc-labeled SBA-16 mesoporous silica nanoparticles.
de Barros AL; de Oliveira Ferraz KS; Dantas TC; Andrade GF; Cardoso VN; Sousa EM
Mater Sci Eng C Mater Biol Appl; 2015 Nov; 56():181-8. PubMed ID: 26249579
[TBL] [Abstract][Full Text] [Related]
16. ImmunoPET imaging of tissue factor expression in pancreatic cancer with
Hernandez R; England CG; Yang Y; Valdovinos HF; Liu B; Wong HC; Barnhart TE; Cai W
J Control Release; 2017 Oct; 264():160-168. PubMed ID: 28843831
[TBL] [Abstract][Full Text] [Related]
17.
Banerjee SR; Foss CA; Horhota A; Pullambhatla M; McDonnell K; Zale S; Pomper MG
Biomacromolecules; 2017 Jan; 18(1):201-209. PubMed ID: 28001364
[TBL] [Abstract][Full Text] [Related]
18. Neutron-activatable holmium-containing mesoporous silica nanoparticles as a potential radionuclide therapeutic agent for ovarian cancer.
Di Pasqua AJ; Yuan H; Chung Y; Kim JK; Huckle JE; Li C; Sadgrove M; Tran TH; Jay M; Lu X
J Nucl Med; 2013 Jan; 54(1):111-6. PubMed ID: 23100452
[TBL] [Abstract][Full Text] [Related]
19. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.
Perk LR; Visser GW; Vosjan MJ; Stigter-van Walsum M; Tijink BM; Leemans CR; van Dongen GA
J Nucl Med; 2005 Nov; 46(11):1898-906. PubMed ID: 16269605
[TBL] [Abstract][Full Text] [Related]
20. Cargo-influences on the biodistribution of hollow mesoporous silica nanoparticles as studied by quantitative
Pochert A; Vernikouskaya I; Pascher F; Rasche V; Lindén M
J Colloid Interface Sci; 2017 Feb; 488():1-9. PubMed ID: 27816633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
